Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DP-R208 Pharmacokinetic Study in Healthy Volunteers
NCT02709187Phase 1Completed
- Sponsor
- Alvogen
- Start
- Mar 2016
- Primary completion
- May 2016
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of candesartan cilexetil + rosuvastatin in hypertension (HTN) and hypercholesterolemia, sponsored by Alvogen. Primary endpoint: Area under the plasma concentration versus time curve at 48 hours. Started Mar 2016; status: completed.
02
Drugs
candesartan cilexetil + rosuvastatin
03
Conditions
hypertension (HTN)hypercholesterolemia
Beyond the preview
Go deeper on NCT02709187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02709187.